Latest Listings And Ipos News

Macarthur Minerals has acknowledged breaching ASX conditions by issuing equity securities without approval and will seek shareholder consent to amend terms and comply with listing rules.

Tasmea Limited forecasts a robust 34% increase in net profit after tax for FY26, driven by a record order book and strategic acquisitions, while reaffirming its FY25 earnings guidance.

Lightning Minerals Ltd has requested a voluntary suspension of its shares on the ASX as it prepares to announce a significant acquisition and capital raising. The suspension is set to last until the announcement or the resumption of trading on 27 June 2025.

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

Augustus Minerals has secured a key position in the Mt Kare Gold Project by acquiring ACM Contract Mining PNG Ltd, positioning itself second-in-line for the exploration license in Papua New Guinea.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Cardiex Limited has successfully raised $4.1 million through a fully underwritten entitlement offer, bringing total funds raised to $6.5 million including a recent institutional placement. The offer saw strong participation from directors and key shareholders, with new shares set to be issued imminently.

archTIS Limited addresses ASX concerns over a sharp rise in its share price, linking the movement to recent contract wins in major defence markets and ongoing acquisition talks in the US.

Eureka Group Holdings has appointed Simon Owen as Managing Director, consolidating his leadership role after serving as CEO since September 2024. The move signals confidence in his vision for growth in the property and rental sectors.

MA Credit Income Trust (ASX, MA1) has successfully raised nearly A$50 million through a wholesale placement, reflecting strong investor appetite for its private credit strategy. The placement was complemented by a significant sell-down of existing units, underscoring robust demand.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Findi Limited has appointed DAM Capital and Ambit as lead managers for the IPO of its Indian subsidiary, Transaction Solutions International, targeting a valuation near A$900 million and a 2026 listing.